Agile Therapeutics Inc financial data

Location
500 College Road East, Suite 310, Princeton, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 53.5 % -36.2%
Quick Ratio 17.1 % +27.6%
Debt-to-equity -180 % +39.2%
Return On Equity 104 % -58.9%
Return On Assets -130 % -0.71%
Operating Margin -62.8 % +72.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.9M shares +258%
Common Stock, Shares, Outstanding 6.9M shares +321%
Entity Public Float 4.8M USD -66.7%
Common Stock, Value, Issued 5K USD
Weighted Average Number of Shares Outstanding, Basic 6.86M shares +287%
Weighted Average Number of Shares Outstanding, Diluted 6.86M shares +287%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 21.6M USD +32.2%
Cost of Revenue 7.84M USD +6.17%
Research and Development Expense 1.79M USD -31.2%
Selling and Marketing Expense 16M USD -26.1%
General and Administrative Expense 9.5M USD -13.4%
Operating Income (Loss) -13.6M USD +63.8%
Nonoperating Income (Expense) -2.3M USD -113%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -15.9M USD +16.8%
Net Income (Loss) Attributable to Parent -15.9M USD +16.8%
Earnings Per Share, Basic 0 USD/shares -100%
Earnings Per Share, Diluted 0 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.85M USD +2.26%
Accounts Receivable, after Allowance for Credit Loss, Current 4.55M USD +2%
Inventory, Net 5.79M USD +128%
Assets, Current 14.4M USD +24%
Property, Plant and Equipment, Net 27K USD -78.6%
Operating Lease, Right-of-Use Asset 255K USD -54.3%
Other Assets, Noncurrent 238K USD 0%
Assets 15M USD +19%
Accounts Payable, Current 16.5M USD +169%
Employee-related Liabilities, Current 954K USD -57.4%
Accrued Liabilities, Current 9.4M USD +39.3%
Liabilities, Current 26.2M USD +71.3%
Operating Lease, Liability, Noncurrent 100K USD -78.5%
Liabilities 36.9M USD +49.3%
Retained Earnings (Accumulated Deficit) -434M USD -3.79%
Stockholders' Equity Attributable to Parent -21.9M USD -80.8%
Liabilities and Equity 15M USD +19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.48M USD -55.2%
Net Cash Provided by (Used in) Financing Activities 2.54M USD +226%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 6.9M shares +321%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 59K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.85M USD +2.26%
Interest Paid, Excluding Capitalized Interest, Operating Activities 50K USD -46.8%
Deferred Tax Assets, Valuation Allowance 100M USD +4.05%
Deferred Tax Assets, Gross 100M USD +4.05%
Operating Lease, Liability 289K USD -54.1%
Depreciation 26K USD 0%
Lessee, Operating Lease, Liability, to be Paid 300K USD -56.7%
Property, Plant and Equipment, Gross 253K USD 0%
Operating Lease, Liability, Current 289K USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 101K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 199K USD -49.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11K USD -82.8%
Deferred Tax Assets, Operating Loss Carryforwards 88.3M USD +1.22%
Preferred Stock, Shares Issued 4.85K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 87K USD +13%
Additional Paid in Capital 412M USD +1.49%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 284K USD -41.1%
Interest Expense 1.2M USD -54.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%